Drug Target Review

OCTOBER 4, 2023

Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised small molecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

JUNE 12, 2023

The current version of Chemistry42 uses over 40 generative models, including generative autoencoders and generative adversarial networks as well as both structure-based and ligand-based drug design to generate and optimise de novo small molecules.

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The Pharma Data

OCTOBER 27, 2020

million in 2015. Primmune aims to advance the development of their novel orally-administered, small molecule toll-like receptor 7 agonists as therapeutic-adjuvants for acute viral diseases and cancer. The $71 million funding includes an initial financing of $32.5 In the U.S., The company’s $27.4

Small Molecule 52

Small Molecule Immune Response Therapies Clinical Development 52

New Drug Approvals

SEPTEMBER 13, 2024

14] Pharmacokinetics The oral bioavailability of aticaprant is 25%. [1] 18] In February 2015, Cerecor Inc. 14] Pharmacokinetics The oral bioavailability of aticaprant is 25%. [1] 18] In February 2015, Cerecor Inc. 11 December 2015. 2] Aticaprant is taken by mouth. [1] nM vs. 24.0 mg dose and 94% for a 10 mg dose.

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

The Pharma Data

OCTOBER 14, 2020

Lanifibranor is believed to be the first drug candidate to be granted this status for the treatment of NASH since January 2015. has expanded its product portfolio to include Blueprint, a self-service, scientific visualization and analytics application for small molecule discovery. Dolmatics – U.K.-based based Dotmatics Ltd.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Therapies 52

Agency IQ

FEBRUARY 23, 2024

Additionally, this approach is generally no longer applicable to new treatments that are more targeted in their effects, such as immunotherapies and targeted small molecule therapies. This workshop built on three prior workshops held by the FDA-AACR, which took place in 2015, 2016 and 2017. . …

Science 40

Science FDA Trials Clinical Pharmacology 40

Agency IQ

DECEMBER 11, 2023

In 2015, the FDA, along with the American Association for Cancer Research (AACR), held a workshop on dose optimization for small molecules. Dose optimization for oncology products has been an issue flagged for improvement even prior to the creation of OCE.

FDA 40

FDA Science Clinical Trials Trials 40